UT MD Anderson – Cancer Center’s Gastrointestinal Medical Oncology Department held its inaugural Colorectal ctDNA Symposium on March 27, 2026. A multidisciplinary group of clinicians and researchers from multiple institutions presented data and discussed how minimal residual disease detection can transform decision‑making, personalize therapy, and close the gap between discovery, community practice, and clinical trials.
Over the next few months, video recordings from select symposium sessions will be posted as they can be released to the public. In this video, Dr. Maen Abdelrahim, GI oncologist at Houston Methodist, discusses the prognostic and predictive implications of MRD in CRC.
